OxyContin maker Purdue Pharma files for bankruptcy


Purdue Pharma, the drugmaker accused of playing a major role in the opioid epidemic, filed for Chapter 11 bankruptcy protection in New York on Sunday. The move was expected after the company and its owners, the Sackler family, reached a tentative settlement with 24 states and thousands of local governments last week. Under the settlement, the Sacklers would wash their hands of Purdue, putting up $3 billion of the family's estimated $13 billion fortune and turning Purdue into a trust, with profits from OxyContin and other drugs going to the plaintiffs.
This isn't the end of the road for Purdue yet, though, as The Associated Press explains.
The thousands of plaintiffs who have not yet signed on to the settlement, including about half of U.S. states, will likely object to the settlement in bankruptcy court, and there are open questions about whether the proposed settlement is really worth $12 billion and how the money would be distributed. Purdue and the lawyers representing the parties that agreed to the settlement argue that nobody is served by long, costly litigation.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Recent court filings suggest much of the Sackler wealth has been stashed offshore since 2008, making it likely out of reach of U.S. plaintiffs, especially if the company dissolves without admitting wrongdoing or being found guilty in court. "The Sacklers are going to be left with plenty of money after this,'' Adam J. Levitin, a bankruptcy expert at Georgetown Law, tells The Washington Post. "There is a desire that the Sacklers pay some blood money, but it's never going to be enough to make everyone happy.''
OxyContin accounts for only a slice of the opioid drugs sold in the U.S., but Purdue's aggressive and misleading marketing is blamed for helping spark the opioid addiction crisis. Since 1999, more than 200,000 people have died from overdoses of prescription opioids.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
How Putin misunderstood his past victories
In Depth Though Vladimir Putin has led Russia to a number of grisly military triumphs, they may have misled him when planning the invasion of Ukraine
-
Crossword: August 18, 2025
The Week's daily crossword
-
Sudoku medium: August 18, 2025
The Week's daily medium sudoku puzzle
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages